The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Open accessAbstract
Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clinical responses to targeted therapies. The difficulty of discovering kinase inhibitors with an appropriate multi-target profile has, however, necessitated the application of combination therapies, which can pose significant clinical development challenges. Epigenetic reader domains of the bromodomain family have recently emerged as novel targets for cancer therapy. Here we report that several clinical kinase inhibitors also inhibit bromodomains with therapeutically relevant potencies and are best classified as dual kinase/bromodomain inhibitors. Nanomolar activity on BRD4 by BI-2536 and TG-101348, clinical PLK1 and JAK2/FLT3 kinase inhibitors, respectively, is particularly noteworthy as these combinations of activities on independent oncogenic pathways exemplify a novel strategy for rational single agent polypharmacological targeting. Furthermore, structure-activity relationships and co-crystal structures identify design features that enable a general platform for the rational design of dual kinase/bromodomain inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationA protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Rapid measurement of binding constants and heats of binding using a new titration calorimeter
Wiseman, T., Williston, S., Brandts, J. F., & Lin, L.-N. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90213-3 · Cited by 2,675
Automated protein model building combined with iterative structure refinement.
Anastassis Perrakis, A., Morris, R. J., & Lamzin, V. S. (1999) · Nature Structural Biology · doi:10.1038/8263 · Cited by 2,431
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Self-citation(1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
Self-citationLikelihood-enhanced fast translation functions
McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., & Read, R. J. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905001617 · Cited by 1,639
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Evaluation of single-crystal X-ray diffraction data from a position-sensitive detector
Kabsch, W. (1988) · Journal of Applied Crystallography · doi:10.1107/s0021889888007903 · Cited by 1,505
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion
Painter, J., & Merritt, E. A. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906005270 · Cited by 1,240
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 735
Self-citationAutomatic indexing of rotation diffraction patterns
Kabsch, W. (1988) · Journal of Applied Crystallography · doi:10.1107/s0021889887009737 · Cited by 555
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310658110 · Cited by 468
Self-citationBromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Self-citationSafety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 398
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., Rodig, S. J., Kung, A. L., Bradner, J. E., & Weinstock, D. M. (2012) · Blood · doi:10.1182/blood-2012-02-413021 · Cited by 374
Lockwood, W. W., Zejnullahu, K., Bradner, J. E., & Varmus, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216363109 · Cited by 327
Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1–C-Mad2 core complex
Hewitt, L., Tighe, A., Santaguida, S., White, A. M., Jones, C. D., Musacchio, A., Green, S., & Taylor, S. S. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201002133 · Cited by 321
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo
Sapkota, G. P., Cummings, L., Newell, F. S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., Hoffmann, M., Schnapp, G., Steegmaier, M., et al. (2007) · Biochemical Journal · doi:10.1042/bj20061088 · Cited by 308
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L. A., Thompson, R. C., Muller, S., Knapp, S., & Wang, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3066 · Cited by 299
Self-citationPFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3292 · Cited by 249
Self-citationHaber, D. A., Gray, N. S., & Baselga, J. (2011) · Cell · doi:10.1016/j.cell.2011.03.026 · Cited by 214
Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing
Fedorov, O., Huber, K., Eisenreich, A., Filippakopoulos, P., King, O., Bullock, A. N., Szklarczyk, D., Jensen, L. J., Fabbro, D., Trappe, J., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.11.009 · Cited by 204
Self-citationMartin, M. P., Olesen, S. H., Georg, G. I., & Schönbrunn, E. (2013) · ACS Chemical Biology · doi:10.1021/cb4003283 · Cited by 158
Kinase Inhibitor Selectivity Profiling Using Differential Scanning Fluorimetry
Fedorov, O., Niesen, F. H., & Knapp, S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-337-0_7 · Cited by 158
Self-citationSimard, J. R., Getlik, M., Grütter, C., Pawar, V. T., Wulfert, S., Rabiller, M., & Rauh, D. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902010p · Cited by 153
Xu, D., Kim, Y. D., Postelnek, J., Vu, M. D., Hu, D., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187740 · Cited by 149
Self-citationA selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation
Bergamini, G., Bell, K., Shimamura, S., Werner, T., Cansfield, A. D., Müller, K., Perrin, J., Rau, C., Ellard, K., Hopf, C., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.957 · Cited by 146
Self-citationCai, Z., Zhang, Y., Borzilleri, R. M., Qian, L., Barbosa, S. A. L., Wei, D. D., Zheng, X., Wu, L., Fan, J., Shi, Z., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7013309 · Cited by 144
Self-citationRoles of p38 MAPKs in invasion and metastasis
Barrantes, I. D. B., & Nebreda, Á. R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110676 · Cited by 144
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery
Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletár, I., Ciulli, A., et al. (2011) · Molecular BioSystems · doi:10.1039/c1mb05099k · Cited by 141
Self-citationPI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
Weigelt, B., Warne, P. H., Lambros, M. B. K., Reis-Filho, J. S., & Downward, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3815 · Cited by 140
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Vidler, L. R., Filippakopoulos, P., Fedorov, O., Picaud, S., Martin, S., Tomsett, M., Woodward, H. L., Brown, N., Knapp, S., & Hoelder, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011302 · Cited by 139
Self-citationResearch Article: Selectivity‐determining Residues in Plk1
Kothe, M., Kohls, D., Low, S., Coli, R., Rennie, G. R., Féru, F., Kuhn, C. F., & Ding, Y. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00594.x · Cited by 131
Chapter 26 Real‐Time and Quantitative Imaging of Mammalian Stress Granules and Processing Bodies
Kedersha, N., Tisdale, S., Hickman, T. T., & Anderson, P. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)02626-8 · Cited by 127
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Smith, C. C., Lasater, E. A., Zhu, X., Lin, K. C., Stewart, W. K., Damon, L. E., Salerno, S. N., & Shah, N. P. (2013) · Blood · doi:10.1182/blood-2012-07-442871 · Cited by 127
Self-citationThe Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
Dittmann, A., Werner, T., Chung, C., Savitski, M. M., Savitski, M. F., Grandi, P., Hopf, C., Lindon, M. J., Neubauer, G., Prinjha, R. K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400789e · Cited by 124
Han, S., Mistry, A., Chang, J. S., Cunningham, D., Griffor, M., Bonnette, P. C., Wang, H., Chrunyk, B. A., Aspnes, G. E., Walker, D. P., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809038200 · Cited by 110
Trusolino, L., & Bertotti, A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0400 · Cited by 86
Li, J., Favata, M. F., Kelley, J. A., Caulder, E., Thomas, B. A., Wen, X., Sparks, R. B., Arvanitis, A., Rogers, J. D., Combs, A. P., et al. (2010) · Neoplasia · doi:10.1593/neo.91192 · Cited by 84
Chemical target and pathway toxicity mechanisms defined in primary human cell systems
Berg, E. L., Yang, J. B., Melrose, J. E., Nguyen, D., Privat, S., Rosler, E. S., Kunkel, E. J., & Ekins, S. (2009) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2009.10.001 · Cited by 84
Kinase inhibitors: a new class of antirheumatic drugs
Kyttaris, V. C. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s25426 · Cited by 70
Use of Kinase Inhibitors to Dissect Signaling Pathways
Cuenda, A., & Alessi, D. R. (2003) · Humana Press eBooks · doi:10.1385/1-59259-054-3:161 · Cited by 69
Tong, Y., Stewart, K. D., Thomas, S. A., Przytulinska, M., Johnson, E. F., Klinghofer, V., Leverson, J. D., McCall, O., Soni, N. B., Luo, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.079 · Cited by 63
Ramakrishnan, V. G., Kimlinger, T. K., Haug, J. L., Timm, M., Wellik, L. E., Halling, T. M., Pardanani, A. D., Tefferi, A., Rajkumar, S. V., & Kumar, S. K. (2010) · American Journal of Hematology · doi:10.1002/ajh.21785 · Cited by 60
Gunawardane, R. N., Nepomuceno, R. R., Rooks, A. M., Hunt, J. P., Ricono, J. M., Belli, B., & Armstrong, R. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0305 · Cited by 48
Self-citation2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors
Siu, M., Pastor, R. M., Liu, W. J., Barrett, K., Berry, M., Blair, W. S., Chang, C., Chen, J. Z., Eigenbrot, C. W., Ghilardi, N., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.008 · Cited by 46
Cited by
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Self-citationKinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
Fujisawa, T., & Filippakopoulos, P. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.143 · Cited by 573
Self-citation
Metadata
- Authors
- Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., Martin, S., Wodicka, L. M., Shah, N. P., Treiber, D. K., & Knapp, S.
- Venue
- Nature Chemical Biology
- Published
- 2014-03-02
- Volume
- 10
- Issue
- 4
- Pages
- 305-312
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2072981794
- Cited by
- 338
- References
- 59
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.